Literature DB >> 34949655

Extent and Instability of Trimethylation of Histone H3 Lysine Increases With Degree of Malignancy and Methionine Addiction.

Jun Yamamoto1,2,3, Yusuke Aoki4,2, Sachiko Inubushi4,2, Qinghong Han4, Kazuyuki Hamada4,2, Yoshihiko Tashiro4,2, Kentaro Miyake3, Ryusei Matsuyama3, Michael Bouvet2, Steven G Clarke5, Itaru Endo6, Robert M Hoffman7,2.   

Abstract

BACKGROUND/AIM: Methionine addiction is a fundamental and general hallmark of cancer, termed the Hoffman effect. Methionine addiction is due to excessive use of and dependence on methionine by cancer cells. In the present report, we correlated the extent of methionine addiction and degree of malignancy with the amount and stability of methylated histone H3 lysine marks.
MATERIALS AND METHODS: We established low- and high-malignancy variants from a parental human pancreatic-cancer cell line and compared their sensitivity to methionine restriction and histone H3 lysine methylation status.
RESULTS: A low-malignancy, low-methionine-addiction revertant of the parental pancreatic-cancer cell line had less methylated H3K9me3 and was less sensitive to methionine restriction effected by recombinant methioninase (rMETase) than the parental cell line. A high-malignancy variant of the pancreatic cancer cell line had increased methylated H3K9me3 and was more sensitive to methionine restriction by rMETase with regard to inhibition of proliferation and to instability of histone H3 lysine methylation than the parental cell line. Orthotopic malignancy in nude mice was reduced in the low-methionine-addiction revertant and greater in the high-malignancy variant than in the parental cell line.
CONCLUSION: The present study indicates that the degree of malignancy is linked to the extent of methionine addiction and the level and instability of trimethylation of histone H3, suggesting these phenomena are linked as a fundamental basis of oncogenic transformation.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Methionine addiction; high-methionine addiction variants; histone H3 lysine; low-methionine-addiction revertant; malignancy; methionine dependence; methionine restriction; overmethylation; transmethylation

Mesh:

Substances:

Year:  2022        PMID: 34949655      PMCID: PMC8717956          DOI: 10.21873/cgp.20299

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  28 in total

1.  High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine.

Authors:  R M Hoffman; R W Erbe
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

2.  Methionine dependency of malignant tumors: a possible approach for therapy.

Authors:  F Breillout; E Antoine; M F Poupon
Journal:  J Natl Cancer Inst       Date:  1990-10-17       Impact factor: 13.506

3.  Reversion from Methionine Addiction to Methionine Independence Results in Loss of Tumorigenic Potential of Highly-malignant Lung-cancer Cells.

Authors:  Jun Yamamoto; Yusuke Aoki; Qinghong Han; Norihiko Sugisawa; Y U Sun; Kazuyuki Hamada; Hiroto Nishino; Sachiko Inubushi; Kentaro Miyake; Ryusei Matsuyama; Michael Bouvet; Itaru Endo; Robert M Hoffman
Journal:  Anticancer Res       Date:  2021-02       Impact factor: 2.480

4.  Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy.

Authors:  Y Tan; M Xu; X Tan; X Tan; X Wang; Y Saikawa; T Nagahama; X Sun; M Lenz; R M Hoffman
Journal:  Protein Expr Purif       Date:  1997-03       Impact factor: 1.650

5.  Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model.

Authors:  Jun Yamamoto; Kentaro Miyake; Qinghong Han; Yuying Tan; Sachiko Inubushi; Norihiko Sugisawa; Takashi Higuchi; Yoshihiko Tashiro; Hiroto Nishino; Yuki Homma; Ryusei Matsuyama; Sant P Chawla; Michael Bouvet; Shree Ram Singh; Itaru Endo; Robert M Hoffman
Journal:  Cancer Lett       Date:  2020-07-31       Impact factor: 8.679

6.  Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo.

Authors:  H Guo; V K Lishko; H Herrera; A Groce; T Kubota; R M Hoffman
Journal:  Cancer Res       Date:  1993-12-01       Impact factor: 12.701

Review 7.  Methionine metabolism in health and cancer: a nexus of diet and precision medicine.

Authors:  Sydney M Sanderson; Xia Gao; Ziwei Dai; Jason W Locasale
Journal:  Nat Rev Cancer       Date:  2019-09-12       Impact factor: 60.716

8.  Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity.

Authors:  Shuya Yano; Shukuan Li; Qinghong Han; Yuying Tan; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Oncotarget       Date:  2014-09-30

Review 9.  Dietary modifications for enhanced cancer therapy.

Authors:  Naama Kanarek; Boryana Petrova; David M Sabatini
Journal:  Nature       Date:  2020-03-25       Impact factor: 49.962

Review 10.  Methionine Dependence of Cancer.

Authors:  Peter Kaiser
Journal:  Biomolecules       Date:  2020-04-08
View more
  3 in total

1.  Deletion of MTAP Highly Sensitizes Osteosarcoma Cells to Methionine Restriction With Recombinant Methioninase.

Authors:  Yusuke Aoki; Yasunori Tome; Qinghong Han; Jun Yamamoto; Kazuyuki Hamada; Noriyuki Masaki; Yutaro Kubota; Michael Bouvet; Kotaro Nishida; Robert M Hoffman
Journal:  Cancer Genomics Proteomics       Date:  2022 May-Jun       Impact factor: 4.069

2.  Linkage of methionine addiction, histone lysine hypermethylation, and malignancy.

Authors:  Jun Yamamoto; Sachiko Inubushi; Qinghong Han; Yoshihiko Tashiro; Norihiko Sugisawa; Kazuyuki Hamada; Yusuke Aoki; Kentaro Miyake; Ryusei Matsuyama; Michael Bouvet; Steven G Clarke; Itaru Endo; Robert M Hoffman
Journal:  iScience       Date:  2022-03-25

Review 3.  Review: Precise sarcoma patient-derived orthotopic xenograft (PDOX) mouse models enable identification of novel effective combination therapies with the cyclin-dependent kinase inhibitor palbociclib: A strategy for clinical application.

Authors:  Takashi Higuchi; Kentaro Igarashi; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Michael Bouvet; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.